Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): Six-year results from a prospective, multicentre, non-interventional study in 2,484 patients

Arthritis Research and Therapy

Volumn 16, Issue 2, 2014, Pages

  Wendler, Joerg ^a   Burmester, Gerd R ^b   Sörensen, Helmut ^c   Krause, Andreas ^d   Richter, Constanze ^e   Tony, Hans Peter ^f   Rubbert Roth, Andrea ^g   Bartz Bazzanella, Peter ^h   Wassenberg, Siegfried ⁱ   Haug Rost, Iris ^j   Dörner, Thomas ^k  

^a Rheumatologische Schwerpunktpraxis   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Rheumaprojekt Berlin Brandenburg   (Germany)

^d MARTIN LUTHER KRANKENHAUS   (Germany)

^e Rheumatology Medical Center   (Germany)

^f UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^g UNIVERSITY OF COLOGNE   (Germany)

^h Klinik fur Internistische Rheumatologie   (Germany)

ⁱ Fachkrankenhaus Ratingen   (Germany)

^j ROCHE INNOVATION CENTER MUNICH   (Germany)

^k DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; RITUXIMAB; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ABSENCE OF SIDE EFFECTS; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ARTICLE; CANDIDIASIS; COHORT ANALYSIS; CONTROLLED STUDY; DAS28; DERMATOMYCOSIS; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FUNGAL SINUSITIS; GERMANY; HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX; HUMAN; INFECTION; INFUSION RELATED REACTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; MYCOSIS; PARASITOSIS; PHYSICIAN; PROSPECTIVE STUDY; PRURITUS; RATING SCALE; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SEPSIS; SEPTIC SHOCK; SKIN DISEASE; THRUSH; TINEA CORPORIS; TINEA PEDIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UROSEPSIS; VAGINA CANDIDIASIS; VULVOVAGINITIS; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84899154465     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4521     Document Type: Article

References (23)

1. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350:2572-2581. 10.1056/NEJMoa032534, 15201414.
2. Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, Dougados M, Baldassare A, Ferraccioli G, Chubick A, Udell J, Cravets MW, Agarwal S, Cooper S, Magrini F. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007, 56:3896-3908. 10.1002/art.23059, 18050221.
3. Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dörner T, Ferraccioli G, Gottenberg JE, Isaacs J, Kvien TK, Mariette X, Martin-Mola E, Pavelka K, Tak PP, van der Heijde D, van Vollenhoven RF, Emery P,. Rituximab Consensus Expert Committee Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011, 70:909-920. 10.1136/ard.2010.144998, 3086093, 21378402, Rituximab Consensus Expert Committee.
4. Keystone EC, Cohen SB, Emery P, Kremer JM, Dougados M, Loveless JE, Chung C, Wong P, Lehane PB, Tyrrell H. Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study. J Rheumatol 2012, 39:2238-2246. 10.3899/jrheum.120573, 23027887.
5. van Vollenhoven RF, Emery P, Bingham CO, Keystone EC, Fleischmann RM, Furst DE, Tyson N, Collinson N, Lehane PB. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with focus on adverse events of interest in RA patients. Ann Rheum Dis 2013, 72:1496-1502. 10.1136/annrheumdis-2012-201956, 3756452, 23136242.
6. Zink A, Strangfeld A, Schneider M, Herzer P, Hierse F, Stoyanova-Scholz M, Wassenberg S, Kapelle A, Listing J. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum 2006, 54:3399-3407. 10.1002/art.22193, 17075823.
7. Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Gabay C, van Riel PL, Nordström DC, Gomez-Reino J, Pavelka K, Tomsic M, Kvien TK, van Vollenhoven RF. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis 2011, 70:1575-1580. 10.1136/ard.2010.148759, 21571731.
8. Gottenberg JE, Ravaud P, Bardin T, Cacoub P, Cantagrel A, Combe B, Dougados M, Flipo RM, Godeau B, Guillevin L, Le Lot X, Haculla E, Schaeverbeke T, Sibilia J, Pane I, Abbe A, Baron G, Mariette X,. French Society of Rheumatology Prospective follow-up of RA patients (3680 patient/year) treated with rituximab in real life: results from the AIR registry [abstract]. Ann Rheum Dis 2011, 70:465. French Society of Rheumatology.
9. Strangfeld A, Eveslage M, Kekow J, Grabetaler A, Kaufmann J, Listing J, Zink A. Effectiveness of treatment with rituximab depends on autoantibody status - results from 2 years of experience in the German biologics register RABBIT [abstract]. Arthritis Rheum 2009, 60:S634-S635.
10. Vander Cruyssen B, Durez P, Westhovens R, Kaiser MJ, Hoffman I, De Keyser F,. MIRA Study Group The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry: clues for the optimization of rituximab treatment strategies. Arthritis Res Ther 2010, 12:R169. 10.1186/ar3129, 2990996, 20831776, MIRA Study Group.
11. Van Vollenhoven RF, Chatzidionysiou K, Nasonov E, Lukina G, Hetland ML, Tarp U, Gabay C, Van Riel PL, Nordstrom DC, Gomez-Reino JJ, Pavelka K, Tomsic M, Lie E, Kvien TK. Six-month results from the collaborative European registries for rituximab in rheumatoid arthritis (CERERRA). Efficacy of rituximab is highest in RF-positive patients and in those who failed at most one prior anti-TNF [abstract]. The 2009 ACR/ARHP Annual Scientific MeetingPhiladelphia, October 16-21, 2009. Arthritis Rheum 2009, 60(suppl):S624-S625.
12. Cleveland WS. Robust locally weighted regression and smoothing scatterplots. J Am Stat Assoc 1979, 74:829-836.
13. Keystone EC, Fleischmann RM, Emery P, Dougados M, Williams S, Linnik MD, Reynard M. Multiple courses of rituximab produce sustained efficacy in patients with rheumatoid arthritis with an inadequate response to one or more TNF Inhibitors [abstract]. Arthritis Rheum 2010, 62(suppl):S133.
14. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, Combe B, Cutolo M, de Wit M, Dougados M, Emery P, Gibofsky A, Gomez-Reino JJ, Haraoui B, Kalden J, Keystone EC, Kvien TK, McInnes I, Martin-Mola E, Montecucco C, Schoels M, van der Heijde D,. T2T Expert Committee Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010, 69:631-637. 10.1136/ard.2009.123919, 3015099, 20215140, T2T Expert Committee.
15. Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D, Buch M, Gossec L, Huizinga T, Bijlsma JW, Burmester G, Combe B, Cutolo M, Gabay C, Gomez-Reino J, Kouloumas M, Kvien TK, Martin-Mola E, McInnes I, Pavelka K, van Riel P, Scholte M, Scott DL, Sokka T, Valesini G, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010, 69:964-975. 10.1136/ard.2009.126532, 2935329, 20444750.
16. MabThera® Summary of product characteristics. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000165/human_med_000897.jsp&mid=WC0b01ac058001d124, MabThera®.
17. Wendler J, Sørensen H, Tony H, Richter C, Krause A, Rubbert-Roth A, Bogdan M, Burmester G. Effectiveness and safety of rituximab (RTX) monotherapy compared to RTX combination therapy with methotrexate or leflunomide in the German RTX-treatment of active rheumatoid arthritis in daily practice trial [abstract]. Ann Rheum Dis 2009, 68:76.
18. Solau-Gervais E, Prudhomme C, Philippe P, Duhamel A, Dupont-Créteur C, Legrand JL, Houvenagel E, Flipo RM. Efficacy of rituximab in the treatment of rheumatoid arthritis. Influence of serologic status, coprescription of methotrexate and prior TNF-alpha inhibitors exposure. Joint Bone Spine 2012, 79:281-284. 10.1016/j.jbspin.2011.05.002, 21724444.
19. Owczarczyk K, Hellmann M, Fliedner G, Röhrs T, Maizus K, Passon D, Hallek M, Rubbert A. Clinical outcome and B cell depletion in patients with rheumatoid arthritis receiving rituximab monotherapy in comparison with patients receiving concomitant methotrexate. Ann Rheum Dis 2008, 67:1648-1650. 10.1136/ard.2007.087023, 18854518.
20. Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, van Riel PL, Nordström DC, Gomez-Reino J, Pavelka K, Tomsic M, Kvien TK, van Vollenhoven RF, Gabay C. Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. Ann Rheum Dis 2012, 71:374-377. 10.1136/annrheumdis-2011-200003, 21972242.
21. Emery P, Dörner T. Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response. Ann Rheum Dis 2011, 70:2063-2070. 10.1136/ard.2010.148015, 22039166.
22. Isaacs JD, Cohen SB, Emery P, Tak PP, Wang J, Lei G, Williams S, Lal P, Read SJ. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann Rheum Dis 2013, 72:329-336. 10.1136/annrheumdis-2011-201117, 22689315.
23. van Vollenhoven RF, Emery P, Bingham CO, Keystone EC, Fleischmann R, Furst DE, Macey K, Sweetser M, Kelman A, Rao R. Long-term safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheum 2010, 37:558-567. 10.3899/jrheum.090856, 20110520.